Boule Diagnostics AB

BOUL

SE0011231158

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2025-06-19 pm EDT			5-day change	1st Jan Change
8.020 ^SEK	0.00%		-2.91%	-10.69%

Jun. 13	Pareto reiterates buy recommendation for Boule – return to positive organic growth expected	FW
Jun. 13	Pareto Securities lowers its target price for Boule Diagnostics to SEK 10.30 (10.50), reiterates buy recommendation	FW

Boule Diagnostics Q1 Adj Oper Profit At SEK 17.0 Mln

Published on 04/28/2025 at 02:05

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Boule Diagnostics AB

Pareto reiterates buy recommendation for Boule – return to positive organic growth expected	Jun. 13	FW
Pareto Securities lowers its target price for Boule Diagnostics to SEK 10.30 (10.50), reiterates buy recommendation	Jun. 13	FW
SEB Enskilda brokers approximately 1.0 percent of the capital in Boule Diagnostics.	Jun. 04	FW
Boule Diagnostics AB, Q1 2025 Earnings Call, Apr 28, 2025	Apr. 28
Stockholm Bullets - Volati rises on interim report, Wallenstam falls	Apr. 28	FW
Boule Diagnostics reports lower sales and operating profit	Apr. 28	FW
Boule Diagnostics Q1 Adj Oper Profit At SEK 17.0 Mln	Apr. 28	RE
Boule Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 28	CI
Third Swedish National Pension Fund reduces its ownership in Boule Diagnostics	Apr. 23	FW
SEB Enskilda brokers a 0.5 percent stake in Boule Diagnostics	Apr. 22	FW
SEB brokers approximately 0.5 percent of the capital in Boule Diagnostics	Apr. 10	FW
Boule Diagnostics calls for Annual General Meeting on May 7	Apr. 07	FW
Pareto makes minor cut in target price for Boule Diagnostics	Mar. 13	FW
Boule Diagnostics Closes BM950 Project, Announces New Portfolio Strategy	Mar. 12	RE
Technical problems halt Boule Diagnostics BM950 project, take write-downs	Mar. 12	FW
Boule Diagnostics takes impairment of 92 million	Mar. 12	FW
Di lists seven potential bid candidates	Mar. 10	FW
Karin Dahllöf declines re-election to the Board of Boule Diagnostics	Feb. 26	FW
Pareto reiterates buy for Boule - discount to peer group expected to narrow	Feb. 12	FW
Pareto Securities raises target price for Boule Diagnostics to SEK 11 (10.50), reiterates Buy	Feb. 12	FW
Boule Diagnostics AB, 2024 Earnings Call, Feb 11, 2025	Feb. 11
Boule Diagnostics decreases turnover but increases adjusted operating profit (update)	Feb. 11	FW
Boule Diagnostics decreases turnover but increases adjusted operating profit	Feb. 11	FW
Boule Diagnostics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Feb. 09	CI
Boule Diagnostics signs distribution agreement with Vital Scientific in the US	Feb. 07	FW

Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.

Employees

200

Sector

Advanced Medical Equipment & Technology

Calendar

Jul. 17 - Q2 2025 Earnings Release

More about the company